Multiple Myeloma
Key Points
Key Points
The estimated number of deaths from multiple myeloma in 2018 is 12,770, representing 2.1% of all cancer deaths.
Despite significant advances and improvements in overall survival, multiple myeloma remains incurable and additional treatments are needed.
The median survival is just over 5 years and most patients receive 4 or more different lines of therapy throughout their disease course.
Treatment
...atment...
...nsplant Eligib...
...hould be referred to a transplant center to det...
...and renal function should not be the sole cr...
...al regimen and number of cycles rema...
...ansplant should be offered to all transplant-eligi...
...ssociated with stem cell toxicity, such as melpha...
...m cell collection (sufficient for more...
...nimal response required to proceed to SCT is n...
...gh-dose melphalan is the recommended conditionin...
...m autologous SCT should not be routine...
...r delayed SCT may be used as consolidatio...
...eneic transplant for multiple myeloma is...
Consolidation therapy is not routinely recommen...
...domide maintenance therapy should be routinel...
...tolerant of or unable to receive le...
...h-risk patients, maintenance therapy...
...insufficient evidence to make modif...
...depth of response should be assessed by IMWG (...
...f initial therapy for transplant eligible pati...
It is recommended that depth of response b...
...ole-body low dose CT scan has been s...
...ransplant Ineligib...
...treatment recommendations for patients with multip...
...al treatment for patients with multi...
...let therapies for patients with multiple m...
...sicians/patients should balance the potentia...
...py should be offered over fixed dur...
...e goal of initial therapy for transplant...
...onse for all patients should be assessed by...
...ufficient evidence to support chan...
...initiation of therapy, one should define patient...
...ommended that patients be monitored closely with c...
...sed Disease...
...ent for biochemically relapsed myeloma should...
...l clinically relapsed patients with...
...py should be administered on first rela...
...f relapsed multiple myeloma may be continue...
...therapies should be taken into considerati...
...us stem cell transplantation, if not received a...
...k status of the patients should be assesse...
...sk assessment at the time of relap...
...nt of other risk factors such as renal i...
...with genetic high-risk disease a t...
...patients with renal insufficiency, drugs sh...
...plasma cell leukemia or extra medul...
...IMWG revised response criteria should...
...l measurable parameters need to be followed in...
...excluding marrow and imaging should be confirme...
...nse assessment should be performed afte...
...re 1. Algorithm On Management of Patients wi...
...Used in the Management of Patients With...
...e 2. Diagnostic Criteria for Active...
...ble 3. Revised International Staging System (R-ISS...
...ble 4. Comparison of Select Risk Prediction M...
...WG Response CriteriaHaving trouble vi...
...imated Cost of Drugs for Multiple MyelomaHaving t...